Herold, J.M.* et al. Population-based reference values for kidney function and kidney function decline in 25- to 95-year-old Germans without and with diabetes. Kidney Int. 106, 699-711 (2024)
Zimmermann, S.* et al. Chronic kidney disease leads to microglial potassium efflux and inflammasome activation in the brain. Kidney Int. 106, 1101-1116 (2024)
Riedhammer, K.M.* et al. Implication of transcription factor FOXD2 dysfunction in syndromic congenital anomalies of the kidney and urinary tract (CAKUT). Kidney Int. 105, 844-864 (2023)
Bissinger, R.* ; Bohnert, B.N. ; Nemkov, T.* & Artunc, F. The authors reply. Kidney Int. 101, 649-650 (2022)
Drovandi, S.* et al. Variation of the clinical spectrum and genotype-phenotype associations in Coenzyme Q10 deficiency associated glomerulopathy. Kidney Int. 102, 592-603 (2022)
Drovandi, S.* et al. Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiency. Kidney Int. 102, 604-612 (2022)
Gorski, M.* et al. Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies. Kidney Int. 102, 624-639 (2022)
Bissinger, R.* et al. Proteinuric chronic kidney disease is associated with altered red blood cell lifespan, deformability and metabolism. Kidney Int. 100, 1227-1239 (2021)
Bohnert, B.N. et al. The Case | A 74-year-old liver transplant recipient with nephrotic-range proteinuria. Kidney Int. 99, 1031-1032 (2021)
Gorski, M.* et al. Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. Kidney Int. 99, 926-939 (2021)
Artunc, F. Kidney-derived PCSK9-a new driver of hyperlipidemia in nephrotic syndrome? Kidney Int. 98, 1393-1395 (2020)
Pastor-Arroyo, E.M.* et al. The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk. Kidney Int. 94, 49-59 (2018)
Bohnert, B.N. et al. Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome. Kidney Int. 93, 159-172 (2017)
Gorski, M.* et al. Genome-wide association study of kidney function decline in individuals of European descent. Kidney Int. 87, 1017–1029 (2015)
Seleznik, G.M.* et al. The lymphotoxin β receptor is a potential therapeutic target in renal inflammation. Kidney Int. 89, 113–126 (2015)
Pattaro, C.* et al. Genome-wide linkage analysis of serum creatinine in three isolated European populations. Kidney Int. 76, 297-306 (2009)
Segerer, S.* et al. Compartment specific expression of dendritic cell markers in human glomerulonephritis. Kidney Int. 74, 37-46 (2008)
Frischmann, M.E.* et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int. 71, 1036-1043 (2007)
Kollerits, B.* ; Fliser, D.* ; Heid, I.M. ; Ritz, E.* & Kronenberg, F.* Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: The Mild to Moderate Kidney Disease Study. Kidney Int. 71, 1279-1286 (2007)
Segerer, S.* et al. Expression of the chemokine receptor CXCR1 in human glomerular disease. Kidney Int. 69, 1765-1773 (2006)
Haiman, M.* et al. Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue. Kidney Int. 68, 1130-1136 (2005)
Kronenberg, F. et al. Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? Kidney Int. 66, 348-354 (2004)
Kronenberg, F. et al. The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. Kidney Int. 65, 606-612 (2004)
Kronenberg, F. et al. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients.  Kidney Int. 63, Suppl.84, 113-116 (2003)
White, K.E.* et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 60, 2079-2086 (2001)